Optimal treatment of early-stage ovarian cancer

F Collinson, W Qian, R Fossati, A Lissoni, C Williams, M Parmar, J Ledermann, N Colombo, A Swart, on behalf of the ICON1 collaborators

Research output: Contribution to journalArticlepeer-review

65 Citations (Scopus)


There is no clear consensus regarding systemic treatment of early-stage ovarian cancer (OC). Clinical trials are challenging because of the relatively low incidence and good prognosis. Initial results of the International Collaborative Ovarian Neoplasm (ICON)1 trial demonstrated benefit in both overall survival (OS) and recurrence-free survival (RFS) with adjuvant chemotherapy. We report results of 10-year follow-up to establish whether benefits are maintained longer-term and discuss how this and other available evidence from randomised trials can be used to guide treatment options regarding the need for, and choice of, adjuvant chemotherapy regimen.
Original languageEnglish
Pages (from-to)1165-1171
Number of pages7
JournalAnnals of Oncology
Issue number6
Early online date14 Mar 2014
Publication statusPublished - Jun 2014


  • early-stage ovarian cancer
  • adjuvant chemotherapy
  • ICON1
  • ICON3

Cite this